Institute of Medical Informatics, China Academy of Chinese Medical Sciences, Beijing, China.
Chin J Integr Med. 2012 Nov;18(11):862-7. doi: 10.1007/s11655-012-1111-1. Epub 2012 Aug 16.
To summarize the effectiveness of Chinese and Western integrative medicine in treating medium and advanced lung cancer, and to provide guidelines for clinical application.
For this metaanalysis, a comparative search of Chinese medicine data in Chinese National Knowledge Infrastructure (CNKI) and Chinese BioMedical Literature Database (CBM) was undertaken to identify articles related to randomized comparative research of Chinese and Western integrative medicine in treating medium and advanced lung cancer between 1996 to 2006. Quality of life (QOL) was estimated using RevMan 4.2 software for data processing, adopting the odd ratio (OR) and the 95% confidence interval (CI).
Through meta-analysis of 10 qualified articles, the results were as follows: the merging effectiveness of QOL [OR=3.80, 95% CI (2.65, 5.47)]; the rate of survival [OR=3.44, 95% CI (2.04, 5.80)]; the tumor response rate [OR=1.88, 95% CI (1.37, 2.58)]; the tumor developing rate [OR=0.33, 95% CI (0.23, 0.48)]. Significant differences existed between the Chinese and Western integrative medicine treatment group and the Western treatment group (P<0.01).
Chinese and Western integrative medicine treatment of medium and advanced lung cancer has shown to improve patients' QOL and survival rate; it also can control tumor development in the short term.
总结中西医结合治疗中晚期肺癌的疗效,为临床应用提供指导。
对中国知识基础设施(CNKI)和中国生物医学文献数据库(CBM)中的中医药数据进行比较检索,以确定 1996 年至 2006 年间中西医结合治疗中晚期肺癌的随机对照研究相关文章。采用 RevMan 4.2 软件进行数据处理,采用比值比(OR)和 95%置信区间(CI)评估生活质量(QOL)。
通过对 10 篇合格文章的荟萃分析,结果如下:QOL 的合并疗效[OR=3.80,95%CI(2.65,5.47)];生存率[OR=3.44,95%CI(2.04,5.80)];肿瘤反应率[OR=1.88,95%CI(1.37,2.58)];肿瘤发展率[OR=0.33,95%CI(0.23,0.48)]。中西医结合治疗组与西医治疗组比较差异有统计学意义(P<0.01)。
中西医结合治疗中晚期肺癌可提高患者的 QOL 和生存率,短期内还能控制肿瘤的发展。